Latest News
-
Rs 44,000 Crore M-Cap Lost, Stock Falls 10%, No More 4th Largest Bank; How RBI's Ban Rocked Kotak -
Mukesh Ambani Led JioCinema Slashes Premium Subscription Prices; IPL Live Stream Remains Free -
Strong Listing: Vodafone Idea FPO Soars In Debut, Shares Rebound; KM Birla Lauds Success -
JPMorgan CEO Jamie Dimon Hails PM Modi's Economic Reforms, Urges US to Follow Suit; Details -
Rs. 60/Share Dividend: Record Date On 28 June; Buy The Bajaj Group Stock For 600% Payout? -
Intraday Trade Call: Day Trading Stock Picks By Chandan Taparia Of Motilal Oswal On Thurday, 25 April -
Trade Setup: Nifty Continues Winning Streak Ahead of April F&O Expiry, Q4 Earnings In Focus -
Rs 10/Share Dividend: Record Date In Due Course; Buy The Banking Stock To Be Eligible? -
Stock Market Live Updates: Indian Market Stable In Green; Sensex Trades At 74,095 Levels, Nifty Up 0.28% -
Tech Mahindra Q4 Results Preview: Revenue May Fall, But Margins Seen To Expand; To Announce Dividend
Multibagger Small Cap Pharma Stock With 432.93% Returns In 3 Years Turning Ex-Dividend In August
Whether there is a recession or not, Dividend stocks have a successful track record, and upon this, if the stock has delivered good returns over the year makes it another promising point to invest. Dividend stocks show that management has the foresight to operate their businesses profitably during good and bad times. Even though it's hard to predict the future of the economy, inflation, or interest rates with absolute confidence, dividend stocks are still considered a good bet.
The name of the company is Kopran Ltd, a small-cap pharmaceuticals company. The company will soon pay the final dividend next month. The stock of the company has delivered multibagger returns in 3 years. Check out the below details to know more about the stock.
Kopran Ltd Final Dividend
Kopran Ltd in its board meeting held on 27th May 2022 has recommended a final dividend of 30% amounting to Rs 3 per equity share for the ending march 2022. Considering the current share price of Rs 195.70, which will result in a dividend yield of 1.53%.
The board of directors of the company in its filing to NSE on 27th May 2022 has stated, "Recommended dividend of Rs. 3.00 per Equity Share of F.V Rs.10 (30%) to the Members of the Company for declaration at the forthcoming 63rd Annual General Meeting."
Added, "In terms of Regulation 30 of the Listing Regulations, please note that the dividend recommended as above, if declared by the Members of the Company at the forthcoming 63rd Annual General Meeting, shall be paid, subject to deduction of tax at source as applicable, on or before 30 days from the date of the Annual General Meeting."
Ex-Dividend Date -The declared dividend ex-dividend date is 04 August 2022. The company has not fixed the record date for the same.
Dividend History
Kopran Ltd has a good track record of Dividends and has delivered 6 dividends since 2001. The company has a good dividend track report and has consistently declared dividends for the last 3 years. In the last 3 years, the company has declared 2 Final & 1 Interim Dividend. The recently declared dividend is a final dividend announced on 27 May 2022.
Kopran Ltd Stock Performance
The current market price of Kopran Ltd is Rs 195.50 per share at the time of writing. Today it slid nearly 0.41% from the previous close. Today it was opened at Rs 199.50. the 52-week low of the stock was recorded at Rs 175.25 per share on 21st June 2022, while the 52-week high was recorded at Rs 370.45 per share on 29 December 2021.
The PE ratio of the stock is 15.60. PB ratio is 2.22. Its face value is Rs 10. EPS-TTM is Rs 12.66. The ROE is 14.32%.
Returns - Kopran Ltd has delivered multibagger returns in 3 years of investments, 432.93%. It has given positive returns of 135.76% in 5 years. However, in past 1 year, the stock has not performed well and has given negative returns of 16.76%. For investment tenure of 1 and 3 months, it has given negative returns of 10.78% and 31.75%, respectively.
About - Kopran Ltd
Kopran Ltd. is an integrated Pharmaceutical Company, committed to manufacturing and supplying International Quality Formulations and Active Pharmaceutical Ingredients worldwide. Kopran's manufacturing facilities and products have accreditations on all continents. Research & Development for New Products and Processes for both Formulations & Active Pharmaceutical Ingredients form the strategy of Kopran's growth.
Disclaimer
The stock has been sourced from NSE. Greynium Information Technologies, the Author, and the respective Brokerage House are not liable for any losses caused as a result of decisions based on the article. Goodreturns.in advises users to check with certified experts before taking any investment decision.
